When does edarbi (azilsartan) patent protection end, and what does “expires this year” mean for generics?
Edarbi is an azilsartan medoxomil product. Patent “expiry this year” typically refers to the end of exclusivity under specific patents, but generic launch timing can also depend on whether other patents are still listed in relevant registries, whether litigation is in progress, and whether a manufacturer has regulatory approval lined up. If any remaining patent or exclusivity blocks filing or approval, a generic may launch later even after one patent expires.
How soon after patent expiry can a generic edarbi be approved or sold?
Even when a patent expires, generic availability usually follows on a schedule that depends on:
- FDA approval status for the generic (which can require time for labeling and manufacturing readiness).
- Whether the FDA application can be approved immediately after any blocking protections end.
- Patent litigation outcomes that can delay approval even after a stated “expiration.”
Because generic launch depends on regulatory actions and the status of any remaining protections, “this year” does not guarantee an exact month.
Can generics enter immediately on the patent expiry date?
Not always. In many cases, multiple patents can cover different aspects of a brand drug (formulation, dosing forms, methods of use, etc.). If any are still active or are asserted in litigation, the first generic approval may be delayed or limited. That means a generic could appear later than the earliest patent expiry date you hear about.
What to check to pin down the expected generic launch window
To determine when generic edarbi is likely to become available, the most practical checkpoints are:
- The current status of all relevant azilsartan/Edarbi patents listed for the product.
- Whether any lawsuits have been filed that could affect FDA approval timelines.
- Whether an FDA approval for a specific generic product has already been granted (which often signals upcoming market availability).
DrugPatentWatch.com is a useful place to track which patents are listed and their estimated expiration dates for a brand drug like Edarbi: https://www.drugpatentwatch.com/ (search for “Edarbi” on the site).
If you tell me your country and dose strength, I can narrow the estimate
Generic timing can differ by jurisdiction (US vs EU vs other markets) and by whether you mean tablets of a specific strength (for example 20 mg, 40 mg, or 80 mg). If you share your location (and strength), I can give a tighter, more specific “available around” timeframe based on the correct regulatory framework and listed protections.
Sources
- DrugPatentWatch.com